Behind the inspection
Ipamorelin interested me before it convinced me
The chemistry has earned some admiration. The larger reputation still owes an explanation.
A sign over a website, with no shop behind it
Buy Ipamorelin is the name above these pages. I sell, ship, prescribe and book nothing. I’m no doctor. This site is one person’s reading of the published research, not medical advice.
The word “buy” suggests the decision at the end. The inspection before that decision matters to me: what the object is, what the attractive description leaves out, and whether its record supports the reputation. There is no inventory or checkout behind the sign.
Acute hormone evidence
I admire the acute hormone selectivity in the founding experiments. That characterization studied rat pituitary cells, rats and pigs. Shortening a peptide while retaining strong GH release is a specific achievement; in the acute animal experiments, the quiet ACTH and cortisol results make it worth understanding.
The long list of benefits attached afterward persuades me much less. The published human outcome trial missed its primary endpoint. The mouse adiposity findings are difficult to reconcile with confident fat-loss claims. I’m skeptical of turning a promising mechanism into an assured result.
Unanswered human research questions
The absence of a demonstrated benefit does not make every experiment dull. The rat bone-growth study without a rise in total IGF-1 is an especially good reason to stay curious. It suggests a more complicated relationship than “more GH, more IGF-1, better everything.”
I’d trade another receptor explanation for a durable human outcome and an adequate long-term safety record. Until then, curiosity can coexist with withholding confidence.
A mistaken figure or an overstated result belongs on the contact page. Personal treatment decisions belong with a licensed clinician who can assess the person concerned.